Mid-term Functional Outcomes of Open Congruent Arc Latarjet for Recurrent Anterior Shoulder Instability: A Retrospective Cohort Study

开放式同心弧Latarjet手术治疗复发性前肩关节不稳的中期功能结果:一项回顾性队列研究

阅读:2

Abstract

INTRODUCTION: Recurrent anterior shoulder instability with significant glenoid bone loss is associated with high failure after isolated soft-tissue repair. The open Latarjet procedure with congruent arc modification improves graft coverage and glenoid arc restoration, but mid-term clinical data are limited. MATERIALS AND METHODS: This retrospective cohort included patients who underwent open Latarjet with congruent arc modification between January 2015 and December 2020. Eligibility criteria were ≥3 anterior dislocations, ≥15% glenoid bone loss, and ≥24 months of follow-up. Functional outcomes (Western Ontario Shoulder Instability Index [WOSI], Rowe), range of motion, complications, and graft union on computed tomography (CT) were assessed. Kaplan-Meier survival analysis estimated recurrence-free survival. RESULTS: A total of 80 patients (62 males, 18 females; mean age 28.5 ± 6.4 years) were analyzed with a mean follow-up of 4.5 ± 1.2 years. WOSI improved from 46.7 ± 12.3 to 79.4 ± 15.8 (P < 0.001), and Rowe from 32.5 ± 9.6 to 85.6 ± 10.7 (P < 0.001), both exceeding minimal clinically important difference thresholds. Forward flexion (+15°) and abduction (+20°) improved significantly, whereas external rotation showed a mild, non-significant reduction (-10°, P = 0.079). Complications occurred in 12.5%, mainly graft non-union (5%). CT confirmed graft union in 95%. Kaplan-Meier analysis showed 97.5% recurrence-free survival at 5 years. CONCLUSION: Open Latarjet with congruent arc modification provides clinically meaningful functional improvement, reliable graft union, and durable mid-term stability in recurrent anterior instability with glenoid bone loss.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。